GlaxoSmithKline plc (ADR) Unusual Bullish Options Activity Means Profits for Traders

 GlaxoSmithKline plc (ADR) Unusual Bullish Options Activity Means Profits for Traders

In today’s session GlaxoSmithKline plc (ADR) (GSK) registered an unusually high (147) contracts volume of call trades. Someone, most probably a professional was a very active buyer of the November, 2016 call, expecting serious GSK increase. With 147 contracts traded and 44524 open interest for the Nov, 16 contract, it seems this is a quite bullish bet. The option with symbol: GSK161118C00045000 closed last at: $0.45 or 12.5% up. About 1.06M shares traded hands. GlaxoSmithKline plc (ADR) (NYSE:GSK) has risen 10.59% since March 3, 2016 and is uptrending. It has outperformed by 2.25% the S&P500.

Analysts await GlaxoSmithKline plc (ADR) (NYSE:GSK) to report earnings on October, 26. They expect $0.77 EPS, up 8.45% or $0.06 from last year’s $0.71 per share. GSK’s profit will be $1.86 billion for 13.93 P/E if the $0.77 EPS becomes a reality. After $0.70 actual EPS reported by GlaxoSmithKline plc (ADR) for the previous quarter, Wall Street now forecasts 10.00% EPS growth.

GlaxoSmithKline plc (ADR) (NYSE:GSK) Ratings Coverage

Out of 10 analysts covering GlaxoSmithKline (NYSE:GSK), 5 rate it a “Buy”, 1 “Sell”, while 4 “Hold”. This means 50% are positive. GlaxoSmithKline has been the topic of 15 analyst reports since September 8, 2015 according to StockzIntelligence Inc. Piperjaffray initiated the stock with “Overweight” rating in Friday, September 23 report. The firm has “Buy” rating by Bank of America given on Wednesday, December 9. The company was maintained on Monday, December 7 by Argus Research. The company was maintained on Friday, August 12 by Argus Research. The firm has “Buy” rating given on Wednesday, January 27 by Bryan Garnier & Cie. The rating was upgraded by Credit Suisse on Tuesday, October 20 to “Neutral”. The company was upgraded on Tuesday, September 15 by BNP Paribas. JP Morgan upgraded the shares of GSK in a report on Monday, October 12 to “Neutral” rating. On Tuesday, September 8 the stock rating was upgraded by Bank of America to “Neutral”. The firm has “Underperform” rating by BNP Paribas given on Wednesday, September 14.

According to Zacks Investment Research, “GlaxoSmithKline is one of the world’s leading research based pharmaceutical and healthcare companies and is committed to improving the quality of human life by enabling people to do more, feel better and live longer. They also have leadership in four major therapeutic areas: anti-infectives, central nervous system (CNS), respiratory and gastro-intestinal/metabolic.”

GlaxoSmithKline plc is a healthcare company. The company has a market cap of $103.47 billion. The Firm is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products. It has a 3191.22 P/E ratio. The Company’s divisions include Pharmaceuticals, Pharmaceuticals R&D, Vaccines and Consumer Healthcare.

GSK Company Profile

GlaxoSmithKline plc (GSK), incorporated on December 6, 1999, is a healthcare company. The Firm is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products. GSK’s principal pharmaceutical products include medicines in various therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, vaccines and human immunodeficiency virus (HIV). The Company’s divisions include Pharmaceuticals, Pharmaceuticals R&D, Vaccines and Consumer Healthcare.

More recent GlaxoSmithKline plc (ADR) (NYSE:GSK) news were published by: Businessfinancenews.com which released: “GlaxoSmithKline plc (ADR) Earning Release; Here’s What to Expect” on July 26, 2016. Also Businessfinancenews.com published the news titled: “Can GlaxoSmithKline plc (ADR) Subsist Advair’s Patent Expiry” on June 25, 2016. Businessfinancenews.com‘s news article titled: “GlaxoSmithKline plc (ADR) Moves Ahead in COPD Treatment” with publication date: May 26, 2016 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Tags:

Related posts

Leave a Comment